An individualized innovative disease management is of great importance for people with
multiple sclerosis (pwMS) to cope with the complexity of this chronic, multidimensional …

There are> 18 distinct disease-modifying therapy (DMT) options covering 10 mechanisms of
action currently approved by the US Food and Drug Administration for the treatment of …

Treatment decisions in multiple sclerosis are complex given the large number of disease-
modifying therapies with diverse safety and efficacy profiles. The importance of early …

Multiple sclerosis is a chronic, inflammatory, and neurodegenerative disease of the central
nervous system and a major cause of neurological disability in young adults. Its prevalence …

Two different treatment paradigms are most often used in multiple sclerosis (MS). An
escalation or induction approach is considered when treating a patient early in the disease …

Author links open overlay panel A. Glaser a, A. Stahmann b, T. Meissner c, P. Flachenecker
d, D. Horáková e, P. Zaratin fg, G. Brichetto gh, M. Pugliatti ij, O. Rienhoff c, S. Vukusic klmn …

In current international classification systems (ICD-10, DSM5), the diagnostic criteria for
psychotic disorders (eg schizophrenia and schizoaffective disorder) are based on …

Background The optimal treatment strategy with disease-modifying therapies (DMTs) in
relapsing–remitting multiple sclerosis (RRMS) remains uncertain. Objective To compare …

Variations in access to health care are known to contribute to differences in life expectancy,
morbidity and health-related quality-of-life across population subgroups. We undertook a …

The concept that HE DMTs are necessarily associated with a high risk of adverse effects, is
no longer supported by the evidence. The rather predictable and manageable risk profile of …